Search Medical Condition
Please enter condition
Please choose location

Wantagh, New York Clinical Trials

A listing of Wantagh, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (257) clinical trials

Safety and Efficacy of KPI-12 in Subjects With Dry Eye Disease

This is a Phase 3, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and efficacy of KPI-121 0.25% ophthalmic suspension versus vehicle in subjects with dry eye disease.

Phase

60.25 miles

Learn More »

This clinical trial is provided by Antidote. People with certain conditions such as Multiple Sclerosis (MS) and Spinal Cord Injury (SCI) may experience urinary incontinence, or involuntary urine loss, as a result of the bladder muscle not relaxing and contracting too often. Oral medications are available but do not work ...

Phase

1.08 miles

Learn More »

Efficacy and Safety of Artacent for Treatment Resistant Lower Extremity Venous and Diabetic Ulcers

This study is to document the efficacy of Artacent™ Human Amniotic Membrane (Artacent) in the treatment of diabetic and vascular lower extremity ulcers. The study will add to the currently available literature by also assessing the impact of treatment on quality of life and on heal economic outcomes. Finally the ...

Phase N/A

1.61 miles

Learn More »

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

The duration per patient is up to 85 weeks, including a Screening Period consisting of a Screening phase of up to 2 weeks and a 2-week single-blind Run-in phase, a 26-week double blind Core Treatment Period, a 53 week double blind Extension, and a 2-week post treatment Follow-up period to ...

Phase

2.76 miles

Learn More »

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes With a FRC Extension Period

The maximum duration for GLP1-RA patients will be approximately 29 weeks: an up to 2 week screening period, a 26 week treatment period (either randomized or uncontrolled), and a 3 or 9 day post-treatment safety followup period. Maximum duration for FRC patients will be approximately 55 weeks: an up to ...

Phase

2.94 miles

Learn More »

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

The registry will be used to evaluate, describe, and document the safety of target-specific anticoagulant agents (and other antithrombotic agents) in patients with Atrial Fibrillation (AF), the clinical outcomes associated with their use, the treatment patterns and clinical course of patients with AF, including those who undergo cardiac procedures of ...

Phase N/A

2.94 miles

Learn More »

Pediatric Residency Training On Tobacco

The American Academy of Pediatrics and other leading health agencies call upon pediatricians to address environmental tobacco smoke (ETS), prevent smoking onset in youths, and encourage cessation of tobacco use by adolescents and their parents. Systematic intervention on tobacco by pediatricians would protect infants and young children from the harmful ...

Phase

3.17 miles

Learn More »